(Albany, US) On October 29, 2026, DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology and Market Forecast – 2036” report provides comprehensive insights into the Familial Adenomatous Polyposis (FAP) market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.
Discover the latest drugs and treatment options in the Familial Adenomatous Polyposis Pipeline @ https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market
Key Takeaways from the Familial Adenomatous Polyposis Report
In March 2025, Biodexa Pharmaceuticals and Emtora Biosciences continued advancing eRAPA in the pivotal Phase III SERENADE trial for FAP, evaluating mTOR inhibition as a chemopreventive strategy to reduce adenoma burden and potentially delay prophylactic colorectal surgery.
In March 2025, Biodexa announced the outcome of its Type C meeting with the US FDA on the planned registrational Phase III protocol for eRAPA. The study is supported by a USD 17 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) and a company match of USD 8.5 million.
In February 2025, the US FDA granted Fast Track Designation to eRAPA for FAP.
In May 2025, Recursion announced preliminary safety and efficacy results from the Phase Ib/II TUPELO trial of REC-4881 in FAP, presented as a late-breaking oral presentation at DDW 2025. REC-4881 has also received FDA Fast Track Designation.
There are currently no approved pharmacological therapies for FAP. Off-label NSAIDs such as sulindac and celecoxib may help reduce polyp burden.
DelveInsight’s report depicts a space where emerging therapies are advancing through mid- to late-stage development, shifting the paradigm from a surgery-centric approach toward chemoprevention and targeted therapy.
Leading Familial Adenomatous Polyposis companies include Emtora Biosciences, Biodexa, Recursion, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Allakos, and others.
Promising therapies include sulindac, celecoxib (CELEBREX), eRAPA, REC-4881, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Familial Adenomatous Polyposis Treatment Drugs
Familial Adenomatous Polyposis Overview
FAP is a rare, inherited, autosomal dominant colorectal cancer predisposition syndrome caused primarily by pathogenic mutations in the APC (adenomatous polyposis coli) gene. It is characterized by hundreds to thousands of adenomatous polyps in the colon and rectum, typically beginning in adolescence or early adulthood. Without treatment, people with classic FAP face an almost 100% lifetime risk of colorectal cancer, often before age 40 to 50. Roughly 20% to 30% of patients have no documented family history and carry de novo APC mutations. Prophylactic colectomy or proctocolectomy remains the standard of care, followed by ongoing surveillance, but surgery does not remove the risk of duodenal polyps, desmoid tumors, or other extracolonic complications. Diagnosis relies on clinical evaluation, family history, colonoscopy, and confirmatory APC genetic testing.
Extracolonic manifestations include:
Duodenal and gastric polyps
Desmoid tumors
Osteomas
Congenital hypertrophy of the retinal pigment epithelium (CHRPE)
Thyroid cancer
Hepatoblastoma
Familial Adenomatous Polyposis Emerging Drugs Profile
eRAPA: Emtora Biosciences and Biodexa Pharmaceuticals eRAPA is a proprietary oral capsule formulation of rapamycin (sirolimus), a small-molecule mTOR inhibitor. Biodexa partnered with Emtora Biosciences in April 2024 to develop, manufacture, and commercialize it. The FDA granted it Fast Track Designation in February 2025, and a registrational Phase III study is planned and supported by CPRIT funding. Currently, the drug is in Phase III.
REC-4881: Recursion REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small-molecule inhibitor of MEK1 and MEK2, being developed to reduce polyp burden and progression to adenocarcinoma in people with FAP. It has received FDA Fast Track Designation. Preliminary Phase Ib/II TUPELO data were presented at DDW 2025. Currently, the drug is in Phase I/II.
Explore groundbreaking therapies and clinical trials in the Familial Adenomatous Polyposis Pipeline @ New Familial Adenomatous Polyposis Treatment Drugs
Familial Adenomatous Polyposis Market Drivers
Greater recognition and genetic testing: Expanded testing, cascade family screening, and improved identification of APC mutations are enabling earlier diagnosis and expanding the addressable patient population.
Significant unmet need beyond surgery: Colectomy does not eliminate duodenal polyps, desmoid tumors, or residual adenomas, and no approved pharmacological therapy exists, creating strong demand for non-surgical options.
Targeted therapy opportunities: Advances in understanding Wnt/β-catenin signaling, APC biology, EGFR pathways, and inflammatory mechanisms are enabling mechanistically diverse candidates such as mTOR and MEK inhibitors.
Mid- to late-stage pipeline progress: eRAPA in Phase III and REC-4881 in Phase I/II are moving toward potential disease-modifying options.
Regulatory and funding support: Fast Track designations and grant funding, such as CPRIT support for the eRAPA Phase III study, are accelerating development.
Growing investment in rare disease: Increasing investment in rare gastrointestinal and hereditary cancer disorders is expanding the competitive landscape.
Precision medicine momentum: Genotype–phenotype correlations, biomarker-driven stratification, and individualized risk assessment support tailored treatment strategies.
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Familial Adenomatous Polyposis Market Drivers and Barriers
Familial Adenomatous Polyposis Market Barriers
Very small patient population: FAP affects roughly 1 in 8,000 to 1 in 30,000 people, making trial recruitment difficult and limiting commercial scale.
Surgery as entrenched standard of care: Prophylactic colectomy and endoscopic surveillance remain the cornerstone of management, and new therapies must show they can delay or reduce surgery.
Low-cost off-label alternatives: Generic NSAIDs such as sulindac and celecoxib are already used to reduce polyp burden, setting a low price benchmark.
No approved precedent: The absence of any approved disease-modifying therapy means regulatory endpoints and reimbursement pathways are still being defined.
Long, complex trials: Slow disease progression and the need for long-term endpoints such as adenoma burden and cancer risk make development lengthy and costly.
Extracolonic disease complexity: Duodenal and desmoid disease are hard to address and may require separate or combined approaches.
Under-recognition and variable testing uptake: Hereditary cancer syndromes are still under-recognized, and genetic testing uptake varies, which can delay diagnosis.
Scope of the Familial Adenomatous Polyposis Report
Coverage: 7MM (US, EU4, UK, Japan)
Companies: As listed above
Therapies: Sulindac, celecoxib (CELEBREX), eRAPA, REC-4881, and others
Assessment by Product Type: Mono, Combination, Mono/Combination
Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight’s in-depth Familial Adenomatous Polyposis report today! @ Familial Adenomatous Polyposis Companies
Table of Contents
Introduction
Executive Summary
Familial Adenomatous Polyposis: Overview
Pipeline Therapeutics
Therapeutic Assessment
DelveInsight’s Analytical Perspective
Late Stage Products (Phase III): eRAPA (Emtora Biosciences/Biodexa Pharmaceuticals)
Mid Stage Products (Phase II): REC-4881 (Recursion), Phase I/II
Early Stage Products (Phase I): REC-4881 (Recursion), Phase I/II
Preclinical and Discovery Stage Products
Inactive Products
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Appendix
About Us
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and infrastructure to clients across the globe.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Mehul MalhotraEmail: Send EmailPhone: 09650213330Address:A-1 NV 89107City: delhiState: IndianaCountry: United StatesWebsite: https://www.delveinsight.com/consulting
